TRVI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions...

Stats
Šios dienos apimtis	64 935.00
Vidutinė apimtis	256 709
Rinkos kapitalizacija	195.11M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $-0.110 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.15
ATR14	$0.0120 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-10	Good Jennifer L	Buy	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Common Stock
2024-05-10	Good Jennifer L	Sell	4 578	Stock Option (right to buy)
2024-02-15	Galletta Christopher	Buy	28 500	Stock Option (right to buy)
2024-02-15	Simon Farrell	Buy	175 000	Stock Option (right to buy)

INSIDER POWER
79.66
Last 98 transactions
Buy: 24 441 332 \| Sell: 1 388 191

Tūris Koreliacija

Ilgas: 0.13 (neutral)

Trumpas: -0.54 (weak negative)

Signal:(42.223) Neutral

Trevi Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Trevi Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.49
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.58
( weak )

-0.55
( weak negative )

-0.39
( neutral )

Trevi Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2023
Pajamos:	$0
Bruto pelnas:	$-123 000 (0.00 %)
EPS:	$-0.290

FY	2022
Pajamos:	$0
Bruto pelnas:	$-43 000.00 (0.00 %)
EPS:	$-0.450

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.830

Financial Reports:

No articles found.

Trevi Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Trevi Therapeutics Inc

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.